Recovery of Phenotypes Obtained by Adaptive Evolution through Inverse Metabolic Engineering

Kuk-Ki Hong\textsuperscript{a,b} and Jens Nielsen\textsuperscript{a,c}

Novo Nordisk Foundation Center for Biosustainability, Department of Chemical and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden\textsuperscript{a}; Research Institute of Biotechnology, CJ CheilJedang, Seoul, Republic of Korea\textsuperscript{b}; and Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Hørsholm, Denmark\textsuperscript{c}

In a previous study, system level analysis of adaptively evolved yeast mutants showing improved galactose utilization revealed relevant mutations. The governing mutations were suggested to be in the Ras/PKA signaling pathway and ergosterol metabolism. Here, site-directed mutants having one of the mutations $\text{RAS2}^{\text{Tyr112}}$, $\text{RAS2}^{\text{Tyr112}}$, and $\text{ERG5}^{\text{Pro370}}$ were constructed and evaluated. The mutants were also combined with overexpression of $\text{PGM2}$, earlier proved as a beneficial target for galactose utilization. The constructed strains were analyzed for their gross phenotype, transcriptome and targeted metabolites, and the results were compared to those obtained from reference strains and the evolved strains. The $\text{RAS2}^{\text{Tyr112}}$ mutation resulted in the highest specific galactose uptake rate among all of the strains with an increased maximum specific growth rate on galactose. The $\text{RAS2}^{\text{Tyr112}}$ mutation also improved the specific galactose uptake rate and also resulted in many transcriptional changes, including ergosterol metabolism. The $\text{ERG5}^{\text{Pro370}}$ mutation only showed a small improvement, but when it was combined with $\text{PGM2}$ overexpression, the phenotype was almost the same as that of the evolved mutants. Combination of the $\text{RAS2}$ mutations with $\text{PGM2}$ overexpression also led to a complete recovery of the adaptive phenotype in galactose utilization. Recovery of the gross phenotype by the reconstructed mutants was achieved with much fewer changes in the genome and transcriptome than for the evolved mutants. Our study demonstrates how the identification of specific mutations by systems biology can direct new metabolic engineering strategies for improving galactose utilization by yeast.

Microbiobased production of fuels and chemicals has been extensively investigated since it may contribute to the establishment of a more sustainable society. In this context, the development of microorganisms with efficient substrate utilization and product formation is a requirement. Evolutionary engineering has traditionally been used for this kind of improvement in industry, since it can result in strategies that are not predicted and hence cannot be obtained through rational design \cite{23}. Evolutionary strategies have gained renewed interest with the progress of tools in systems biology since this has allowed for the identification of governing mutations that can subsequently be implemented through site-directed mutagenesis using the concept of inverse metabolic engineering \cite{1, 15}. Furthermore, understanding the evolution process is useful for the identification of novel metabolic engineering strategies \cite{2, 5}. One of the typical patterns during adaptive evolution is the saturation of fitness with a proportional increase of mutations with the number of generations \cite{2, 10}. This phenomenon seems to be partially explained by the accumulation of deleterious mutations. Therefore, introduction of beneficial mutations into a parental strain to remove negative mutations is normally the last step when evolutionary engineering is used for strain development \cite{25}. Another finding from adaptive evolution studies is that the decline of fitness is due to negative epistasis among beneficial mutations, which means that the impact of combining beneficial mutations is less than the sum of individual mutations \cite{4, 20}. This finding suggests that different combinations of beneficial genetic changes may result in more advanced phenotype, and this opens the way for multiple inverse metabolic engineering strategies.

In a previous study we characterized evolved mutants of yeast that showed improved galactose utilization compared to a reference strain \cite{17}. Three isolated mutants from different populations derived from identical adaptive evolution processes were analyzed by using systems biology tools, and the evolved mutants were also compared to metabolically engineered strains. No mutations were detected in known galactose pathway and regulatory pathways, whereas all three evolved mutants had mutations in the Ras/PKA signaling pathway, and application of one of these mutations showed an improved specific galactose uptake rate. One unique mutation that may link with specific changes of transcripts and metabolites in the ergosterol pathway was also identified, namely, a mutation in $\text{ERG5}$. In addition to the above-mentioned mutations, $\text{PGM2}$ encoding phosphoglucomutase was validated as a metabolic engineering target since it was found to be overexpressed in all of the evolved mutants, which was consistent with the earlier finding that overexpression of this enzyme resulted in improved galactose uptake \cite{3, 13, 17}, whereas overexpression of $\text{GAL}$ genes either individually or in combination does not result in increased galactose uptake \cite{7}. We therefore constructed site-directed mutants that have each of the identified mutations and combined them with $\text{PGM2}$ overexpression to evaluate how much the phenotypes of the adaptively evolved mutants could be recovered by these defined genetic changes. The site-directed mutants were constructed by introducing three point mutations, $\text{RAS2}^{\text{Tyr112}}$(from evolved mutant 62A), $\text{RAS2}^{\text{Tyr112}}$ (from evolved...
TABLE 1 Yeast strains used in this study

<table>
<thead>
<tr>
<th>Strain</th>
<th>Genotype</th>
<th>Group</th>
<th>Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>7D</td>
<td>MATa SEC2 MAL2-8C (CEN.PK113-7D)</td>
<td>Reference strain</td>
<td>SR&amp;D</td>
</tr>
<tr>
<td>62A</td>
<td>7D; total 21 SNPs, including RAS2&lt;sup&gt;Δ577&lt;/sup&gt;</td>
<td>Evolved mutants</td>
<td>17</td>
</tr>
<tr>
<td>62B</td>
<td>7D; total of 104 SNPs, including RAS2&lt;sup&gt;Δ577&lt;/sup&gt; and ERG5&lt;sup&gt;Δ570&lt;/sup&gt;</td>
<td>Evolved mutants</td>
<td>17</td>
</tr>
<tr>
<td>5D</td>
<td>MATa SEC2 MAL2-8C ura3-52 (CEN.PK113-5D)</td>
<td>Reference strain</td>
<td>SR&amp;D</td>
</tr>
<tr>
<td>5DU</td>
<td>5D, pssp-GM2(URA3)</td>
<td>Reference strain</td>
<td>This study</td>
</tr>
<tr>
<td>RAU</td>
<td>5D, pssp-GM2(URA3); RAS2&lt;sup&gt;Δ577&lt;/sup&gt; (from 62A)</td>
<td>Site-directed mutants</td>
<td>This study</td>
</tr>
<tr>
<td>RBU</td>
<td>5D, pssp-GM2(URA3); RAS2&lt;sup&gt;Δ577&lt;/sup&gt; (from 62B)</td>
<td>Site-directed mutants</td>
<td>This study</td>
</tr>
<tr>
<td>EBU</td>
<td>5D, pssp-GM2(URA3); ERG5&lt;sup&gt;Δ570&lt;/sup&gt; (from 62B)</td>
<td>Site-directed mutants</td>
<td>This study</td>
</tr>
<tr>
<td>PGM2</td>
<td>5D, ppgm2(URA3, P&lt;sub&gt;PPMA1&lt;/sub&gt;-PGM2)</td>
<td>Engineered mutant</td>
<td>3</td>
</tr>
<tr>
<td>RAP</td>
<td>5D, ppgm2(URA3, P&lt;sub&gt;PPMA1&lt;/sub&gt;-PGM2); RAS2&lt;sup&gt;Δ577&lt;/sup&gt;</td>
<td>Combined mutants</td>
<td>This study</td>
</tr>
<tr>
<td>RBP</td>
<td>5D, ppgm2(URA3, P&lt;sub&gt;PPMA1&lt;/sub&gt;-PGM2); RAS2&lt;sup&gt;Δ577&lt;/sup&gt;</td>
<td>Combined mutants</td>
<td>This study</td>
</tr>
<tr>
<td>EBP</td>
<td>5D, ppgm2(URA3, P&lt;sub&gt;PPMA1&lt;/sub&gt;-PGM2); ERG5&lt;sup&gt;Δ570&lt;/sup&gt;</td>
<td>Combined mutants</td>
<td>This study</td>
</tr>
</tbody>
</table>

- **a** SR&D, Scientific Research & Development GmbH, Oberursel, Germany.
- **b** The plasmid was added in the present study.

Mutant 62B), and ERG5<sup>Δ570</sup> (from evolved mutant 62B) to a reference strain, and the mutants were further engineered by transformation of a high-copy-number plasmid with constitutive promoter for overexpression of PGM2. We present the results of a comparative analysis of the mutants with only site-directed mutations and mutants with a combination of site-directed mutations and PGM2 overexpression. All of the engineered strains were compared to a reference strain, a previously constructed strain, and the two evolved strains. The comparative analysis involved quantitative fermentation physiology and measurement of the transcriptome and targeted intracellular metabolites. Based on our analysis of the constructed mutants, additional strategies for improving galactose utilization are discussed together with the use of adaptive evolution for improving strain performance.

**MATERIALS AND METHODS**

**Yeast strains and plasmids.** The Saccharomyces cerevisiae strains used in the present study are summarized in Table 1. S. cerevisiae CEN.PK113-5D was used to construct site-directed mutants and combined mutants due to the availability of the URA3 marker gene with the same genotype background as strain 7D except for that particular gene. Reference strains, evolved mutants and site-directed mutants, were preserved on a synthetic ground as strain 7D except for that particular gene. Reference strains, and background subtraction was therefore based on the 7D strain.

**Strain construction and cultivation.** Site-directed mutants were constructed by a previously described method (17). Three point mutations—RAS2<sup>Δ577</sup> (identified in evolved mutant 62A), RAS2<sup>Δ577</sup> (identified in evolved mutant 62B), and ERG5<sup>Δ570</sup> (identified in evolved mutant 62B)—were introduced into strain CEN.PK113-5D separately. The oligomers used in the present study are summarized in Table 2. Approximately 1 kb of sequence, including the mutation in the center region and part of URA3 gene (ca. 20 to 22 mer) in the end, was amplified by PCR. The marker gene URA3 was amplified into two parts. The 5’-end (716 bp) and the 3’-end (1,028 bp) of the URA3 gene were amplified separately. Fusion PCR between the 1-kb sequence and each partial URA3 was implemented, and then two cassettes were prepared. The cassettes were transformed into *S. cerevisiae* CEN.PK113-5D, and the sequence that had the mutation in the target gene together with the URA3 marker was integrated into the chromosome by homologous recombination. The strains that had URA3 could be screened out in selection medium, which was SD medium without uracil. These strains were streaked onto the same medium one more time to purify single colonies. The single isolate clones were streaked onto 5-fluoorotic (5-FOA) acid medium, which consisted of SD medium supplemented with 30 mg of uracil and 750 mg of 5-fluoorotic acid monohydrate (Formedium)/liter, to loop out the URA3 marker. In this process, two types of clones were obtained: one containing the point mutation in the target gene and the other with the wild-type sequence of the target gene. The site-directed mutants were selected through colony PCR by comparing different concentration of PCR product when the primer that had the mutation at the 3’ end was used. To check the selected clones, the genes were sequenced, and presence of the site-directed mutation was confirmed. Finally, prototrophic site-directed mutants (strains RAU, RBU, and EBU) were constructed by transformation with the plasmid, pssp-GM2 containing the URA3 gene. The combined mutants RAP, RBP, and EBP were constructed by transformation of the plasmid pPGM2 into the site-directed mutants. The culture medium and condition used in the present study were as described earlier (17). The fermentation physiology data for *S. cerevisiae* strains CEN.PK113-7D, PGM2, 62A, and 62B were generated in a previous study (17).

**Transcriptome analysis.** The transcriptome was measured by using Affymetrix Yeast Genome 2.0 arrays. The set of differentially expressed genes (the Limma test [Bioconductor] obtained using R Language version 2.13.2 was applied [adjusted P value of <0.01]) were analyzed by comparing the site-directed mutants, the combined mutants, and the PGM2 strain after background subtraction of the transcriptome of the 5DU strain. A second set of differentially expressed genes (adjusted P value of <0.01) was identified by observing the contrast among the combined mutants and the evolved mutants. For the evolved mutants, the parental strain is 7D, and background subtraction was therefore based on the 7D strain. The transcriptome data for *S. cerevisiae* strains CEN.PK113-7D, PGM2, 62A, and 62B were as published in a previous study (17). Functional gene enrichment was done by using the updated gProfiler (24). The heat maps of specific pathways were visualized by using MultiExperiment Viewer software (Dana-Farber Cancer Institute, Boston, MA).

**Gene expression data.** Gene expression data were deposited in the Gene Expression Omnibus database under accession number GSE36118.

**Analysis of carbohydrates and sterols.** Harvested cells were directly used for the extraction of carbohydrates and sterols at 10 and 100 mg (cell dry weight), respectively. The quantification of carbohydrates (trehalose and glycogen) and sterols (ergosterol and dihydroergosterol) used in the present study was described earlier (17). The metabolite concentration...
data of the CEN.PK113-7D, PGM2, 62A, and 62B strains were measured in a previous study (17) and used for combined analysis here.

RESULTS

Fermentation physiology of reconstructed mutants. The S. cerevisiae strains used in the present study are summarized in Table 1. Three point mutations—RAS2 Lys77 (identified in evolved mutant 62A), RAS2 Tyr112 (identified in evolved mutant 62B), and ERG5 Pro370 (identified in evolved mutant 62B)—were introduced into the CEN.PK113-5D strain separately. To avoid uracil supplementation-related effects, an empty plasmid having the URA3 gene as a marker, pSP-GM2, was transformed into the CEN.PK113-5D strain and the strains carrying the site-directed mutations. The resulting prototrophic strains were designated 5DU (reference strain), RAU (carrying RAS2 Lys77), RBU (carrying RAS2 Tyr112), and EBU (carrying ERG5 Pro370). Based on a comparison of these four strains, it was found that each of the single point mutations resulted in an improvement of both the maximum specific growth rate and the specific galactose uptake rate (Fig. 1). The largest effect was observed for RAU, and this single mutation resulted in a 42% increase in the maximum specific growth rate and a 57% increase in the specific galactose uptake rate compared to the reference strain 5DU. This improvement was much greater than what was observed in the evolved mutants 62A and 62B derived from the prototrophic CEN.PK113-7D strain, namely, a 23 to 24% increase in the maximum specific growth rate and a 18 to 26% increase in the maximum specific galactose uptake rate. Although that for the RBU strain that carries another point mutation in the same gene (RAS2), the improvement of galactose utilization was much less. The EBU strain showed the smallest increase of galactose utilization among the three site-directed mutants.

Combination of the beneficial point mutations with overexpression...

TABLE 2 Oligomers used in this study

<table>
<thead>
<tr>
<th>Target</th>
<th>Oligomer Sequence (5′→3′)</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>URA3</td>
<td>URA3-5P1 TTCGGCGTCTAGGGCAATTC</td>
<td>Half of URA3 (5′ URA3)</td>
</tr>
<tr>
<td></td>
<td>URA3-3P1 GAGGAAATGACCCAGAATC</td>
<td>Half of URA3 (3′ URA3)</td>
</tr>
<tr>
<td></td>
<td>URA3-5P2 CTTGAGTGCTGAGTACCGTGCA</td>
<td>Half of URA3 (3′ URA3)</td>
</tr>
<tr>
<td></td>
<td>URA3-3P2 ATCCGATAGCCGATAGCTGGT</td>
<td>Half of URA3 (3′ URA3)</td>
</tr>
<tr>
<td>RAS2</td>
<td>RAS2-5P1 CGACCTTTATCGAATTCC</td>
<td>Fusion with 5′ URA3</td>
</tr>
<tr>
<td></td>
<td>RAS2-3P1 GGAATTCGATAGCCGATAGCTGGT</td>
<td>Fusion with 5′ URA3</td>
</tr>
<tr>
<td></td>
<td>RAS2-5P2 CCCGTTGCAACGAATTCC</td>
<td>Fusion with 3′ URA3</td>
</tr>
<tr>
<td>ERG5</td>
<td>ERG5-5P1 CGCCTTATCATTGGAAC</td>
<td>Fusion with 5′ URA3</td>
</tr>
<tr>
<td></td>
<td>ERG5-3P1 GGAATTCGATAGCCGATAGCTGGT</td>
<td>Fusion with 3′ URA3</td>
</tr>
<tr>
<td></td>
<td>ERG5-5P2 CCCGTTGCAACGAATTCC</td>
<td>Fusion with 3′ URA3</td>
</tr>
<tr>
<td></td>
<td>ERG5-3P2 GGAATTCGATAGCCGATAGCTGGT</td>
<td>Fusion with 3′ URA3</td>
</tr>
</tbody>
</table>

* Sequences used for making fusion regions with URA3 are marked in boldface. Different sequences used to separate wild-type and mutant are underlined.

FIG 1 Data for the overall fermentation physiology of the site-directed mutants (RAU, RBU, and EBU) and the combined mutants (RAP, RBP, and EBP) compared to the reference strains 5DU and 7D, the engineered strain PGM2, and the corresponding evolved mutants 62A and 62B. (A) Correlation between maximum specific growth rate and biomass yield. (B) Correlation between maximum specific galactose uptake rate and specific ethanol production rate. The arrows indicate the relation between reference strains and mutants. Error bars represent the standard deviations from biological duplicates.
expression of PGM2 was evaluated by transformation of pPGM2, including the URA3 marker instead of the empty plasmid pSP-GM2 into the site-directed mutants and the reference strain CEN.PK113-5D, and the resulting strains were named RAP, RBP, EBP, and PGM2 (Table 1). The PGM2 strain exhibited a 27% increase of the maximum specific growth rate and a 40% increase of the specific galactose uptake rate compared to 5DU. These improvements were better than those observed for the RBU and EBU strains (Fig. 1) but consistent with what we have reported earlier (3). Combination of the single point mutations from the evolved mutants and PGM2 overexpression resulted in strains that have gross phenotypes that are almost completely identical to those of the evolved mutants, i.e., in terms of the maximum specific growth rate on galactose, the specific galactose uptake rate and the specific ethanol production rate, they were very similar (Fig. 1; see Table S1 in the supplemental material). The two mutations in RAS2, as well as the ERG5Pro370 mutation, combined with PGM2 overexpression, resulted in a ca. 60% increase in the maximum specific growth rate and a 35 to 50% increase in the specific galactose uptake rate. This is remarkable since the two reference strains 5DU and 7D showed some differences in terms of the maximum specific growth rate, but RAP, RBP, and EBP still reached the same level of galactose utilization as the evolved mutants. We performed an evaluation of the overall carbon fluxes, and this shows that the addition of PGM2 overexpression in the single point mutations resulted in increased respiration and reduced fermentation even with the increase in the maximum specific growth rate (Fig. 2; see Table S2 in the supplemental material). The biomass yield for the combined mutants (RAP, RBP, and EBP) showed a range similar to those for the evolved mutants.

Molecular differences among the reconstructed mutants. The site-directed mutants (RAU, RBU, and EBU), the PGM2 strain, and the combined mutants (RAP, RBP, and EBP) were compared to find common and unique changes in their transcriptomes (Fig. 3). The transcriptome in each strain was compared to the reference strain (CEN.PK113-5D containing an empty plasm-
and genes with significant changes in their transcription were identified (correcting for multiple testing). Conserved transcriptional changes in the different mutants were evaluated using Venn diagrams as illustrated in Fig. 3. The PGM2 strain showed the largest number of transcriptional alterations among all of the reconstructed mutants (762 significantly changed genes), whereas the combined mutants, even though they also have PGM2 overexpression, had much lower number of genes with significant changed transcription, i.e., around 150 to 300 genes. Functional enrichment based on the GO term database for the transcriptional changes in the PGM2 strain was mostly in organelle-related genes (Fig. 3; see also data set S1 in the supplemental material). A functional category of genes with significant changes in transcription in the combined mutants RAP and EBP was ERK/MAPK target related genes based on the REACTOME database. The RBU strain also showed many more transcriptional changes (389 upregulated and 185 downregulated) than RAU (85 upregulated and 59 downregulated). Especially, one of the gene enrichment categories in the uniquely upregulated genes of RBU (254 genes) was ergosterol regulated. Especially, one of the gene enrichment categories in the uniquely upregulated genes of RBU (254 genes) was ergosterol regulated. The other common change in the combined mutants and the evolved mutants was the functional category of ERK/MPPK targets. Genes involved in the ergosterol pathway were therefore analyzed in more detail (Fig. 4). All strains that have mutation of ERG5Pro370 showed overall upregulation of ERG genes and a higher ratio of dihydroergosterol to ergosterol. The mutation of RAS2Tyr112 also showed this pattern, while the combination of this mutation with PGM2 overexpression results in a loss of this pattern (RBP strain). The mutation of ERG5Pro370 had no significant changes in its transcriptome except for five genes in the ergosterol pathway, which are significantly upregulated. The combination with PGM2 overexpression (EBP strain), however, induced more transcriptional changes, but when this strain is compared to the PGM2 strain, the change in the transcriptome is much smaller.

Comparison to evolved mutants. We next compared the reconstructed strains with the evolved mutants at the transcriptome level to analyze mutual and exclusive changes in their transcriptome (Fig. 5). The transcriptome of the evolved strains, 62A and 62B, was analyzed in our earlier study (17) and was found to display a much larger number of transcriptional changes than all of the reconstructed mutants, i.e., around 700 to 1,100 genes had significant changes in their transcription. The result of functional enrichments for uniquely changed genes in the evolved mutants included reserve carbohydrate metabolism (Fig. 5; see also data set S2 in the supplemental material). The reconstructed strains RAU and RAP covered only 7.5 and 8.7% of the transcriptional changes of the 62A evolved mutant, respectively. The RBU strain showed 23.3% of coverage of the transcriptional changes of the 62B evolved mutant, whereas the combined mutant, RBP covered only 8.2% of the transcriptional changes. In case of the ERG5Pro370 mutation derived from the evolved mutant 62B (EBU strain), only 0.4% of the transcriptional changes of the 62B strain were covered. However, when PGM2 overexpression was introduced together with the ERG5Pro370 mutation (EBP strain), almost 12.3% of the transcriptional changes in 62B were covered. The common change in all of the strains that showed improved galactose availability was upregulation of PGM2. The other common change in the combined mutants and the evolved mutants was the functional category of ERK/MPPK targets. Genes involved in the ergosterol pathway were detected to have significantly changed expression in both RBU and 62B, whereas this is not the case for the RBP strain. Also, the common change among the EBU, EBP, and 62B strains was genes of the ergosterol pathway based on the KEGG database.

Changes in galactose and reserve carbohydrate metabolism. The effects of the mutations in RAS2 for regulation of PGM2 and reserve carbohydrate metabolism were analyzed in terms of transcripts and metabolites. The mutations, RAS2Tyr112 and RAS2Tyr112, induced upregulation of PGM2 but not reserve carbohydrate metabolism (Fig. 6). The level of PGM2 upregulation by the mutations in RAS2 was similar to what is found in the PGM2 strain that have overexpression of PGM2 through constitutive expression using a high-copy-number plasmid. Transcripts and metabolites in reserve carbohydrate metabolism showed no comparable changes for any of the reconstructed mutants as found for the evolved mutants 62A and 62B.

DISCUSSION

Few genetic and transcriptional changes are required to reach adaptive phenotypes. During adaptive evolution, there is the possibility of having negative or neutral mutations, and these may be inherited for many generations, since their effect could be com-
compensated for by other beneficial mutations (10). Identification of beneficial mutations and removing negative mutations is clearly one of the important points in strain development (25). Negative epistasis among beneficial mutations is also possible (20). In *Escherichia coli* undergoing adaptive evolution it has been found that spontaneous mutations appear proportionally with the number of cell generations; however, the increase of fitness to a specific environment showed a saturation pattern (2). There are therefore clear discordances between the mutation generation rate and the adaptation rate. Recently, this observation has been explained by the concept of diminishing return epistasis among beneficial mutations (4,20). *E. coli* generated and accumulated beneficial mutations; however, the improvement of fitness resulting from their combination was less than that obtained as the sum of the individual mutations. Therefore, interaction among beneficial mutations could be negative for phenotypic progress. In other words,

**FIG 5** Comparison of the reconstructed strains to the evolved strains 62A and 62B through differentially expressed genes. Differentially expressed genes ($P < 0.01$) are categorized as Venn diagrams. The functional enrichment of genes in each part was analyzed by the hypergeometric distribution based on the KEGG, Reactome, and GO term databases. Red text indicates upregulation, and green text indicates downregulation.

**FIG 6** Changes in galactose and reserve carbohydrate metabolism in reconstructed strains are shown as fold changes in the transcriptome and the concentrations of the carbohydrates. (A) Fold changes among all genes involved in galactose and reserve carbohydrate metabolism are compared to the reference strains. (B) Concentrations of glycogen. (C) Concentrations of trehalose. Error bars represent standard deviations from biological duplicates.
expressed phenotypes may be changeable depending on the combination of beneficial changes. This phenomenon should be very carefully considered in metabolic engineering as the reconstruction of strains based on a combination of beneficial targets identified in evolved mutants may result in improved strains since it not only results in removing negative or neutral mutations but also removes negative epistasis effects. Evolved mutant 62A achieved improved galactose availability with 21 point mutations, including 6 mutations in the coding regions (17), whereas the site-directed mutant RAU showed an even higher specific galactose uptake rate with only one point mutation RAS2Lys77 identified in 62A with a much reduced overall transcriptional alteration. Strain 62A showed a slightly higher maximum specific growth rate than strain RAU; however, based on comparison to the corresponding reference strains 5DU and 7D, respectively, the improvement in specific growth rate was much higher for RAU. It is unclear why the two reference strains showed differences in terms of the maximum specific growth rate and biomass yield. Their transcriptional differences indicate the changes in cell wall and membrane composition (see data set S3 in the supplemental material), and this may be generated by different Urp3p activity because of different copy numbers. The combined mutants RAP, RBP, and EBP, even though they underwent far fewer genetic and molecular changes than the evolved mutants, also achieved almost the same galactose utilization as the evolved ones. These results indicate that fewer genetic changes leading to less transcriptional alteration resulted in better performance of the strain compared to the cumulative mutations obtained from adaptive evolution. The changes in reserve carbohydrate metabolism were considered critical for galactose utilization because of not only common changes in the three evolved mutants but also close linkage with galactose metabolism by sharing metabolites (17). However, the reconstructed mutants obtained the same gross phenotype as the evolved mutants without any changes in reserve carbohydrate metabolism. This finding indicates that all changes occurring in connection with adaptive evolution, even those present in different evolved mutants, may be at least nonessential for improving the phenotype. There could, however, be a beneficial effect of the change in reserve carbohydrate metabolism observed in all of the evolved mutants, and it is possible that this effect was not detected here. However, it seems that many changes that are not related to galactose utilization appeared during the adaptive evolution.

RAS2Lys77 (RAU) and RAS2Tyr112 (RBU) induced the upregulation of PGM2 but not reserve carbohydrate metabolism, and RAS2Tyr112 (RBU) and ERG5Pro370 (EBU) upregulate the ergosterol pathway. In our previous study we inferred that the identified mutations in the Ras/PKA signaling pathway may have triggered the upregulation of PGM2 and reserve carbohydrates metabolism because not only were the mutations identified in all of the evolved mutants but also on the promoter region of PGM2, and genes involved in reserve carbohydrate metabolism contained STER elements involved in Ras activation (27). The upregulation of PGM2 in the evolved strains could increase galactose utilization as proven in earlier studies (3, 13, 17, 21). In the present study, the mutations RAS2Lys77 (RAU) and RAS2Tyr112 (RBU) showed a certain relation to the upregulation of PGM2 but not to any changes in reserve carbohydrate metabolism. The Ras/PKA signaling pathway is involved in glucose sensing, stress response, and many other cellular functions (27). The Ras2 protein is one of the regulatory components that control the activity of protein kinase A (PKA). Ras2 interacts with several molecules such as GTP, guanine exchange factor (Cdc25), GTPase, and adenylate cyclase (Cyr1), and protein structure studies to elucidate binding site with those molecules have been implemented using site-directed mutations (14, 26). One of the mutations RAS2Tyr112 in yeast has been well investigated by evaluating its effect on PKA activity and cellular metabolism (16, 18). Incorporation of that mutation resulted in constitutive activation of PKA by strong GTP binding through inhibition of GTPase (26). The effects of the mutation were the transcriptional downregulation of genes in galactose metabolism and reduction of glycogen accumulation (18). The mutations RAS2Lys77 (RAU) and RAS2Tyr112 (RBU) in the present study seem to have more complex roles than the change in PKA activity. Their positions in RAS2 are not directly involved in known binding sites of molecules (26). No changes in galactose metabolic genes (GAL1, GAL7, and GAL10) were detected (Fig. 6A). In addition to these different effects compared to mutations in other studies such as RAS2Tyr112 mutation, the RAS2Lys77 (RAU) and RAS2Tyr112 (RBU) mutations showed their unique features in terms of differences in the extent of galactose utilization and the induction of transcriptional changes. One of the unique changes in RAS2Tyr112 (RBU) was a change in the expression of genes involved in the ergosterol pathway (Fig. 4). The transcriptional level of ERG genes and the ratio of ergosterol and dihydroergosterol in this mutant were very similar to those for the strain containing the ERG5Pro370 (EBU) mutation. There have been no reports of a direct relationship between Ras2 and ergosterol metabolism in yeast. This phenomenon seems to be a distinctive feature of the RAS2Tyr112 (RBU) mutation.

Concerning the effect of the ERG5 mutation on galactose metabolism, we speculate that the higher amount of dihydroergosterol instead of ergosterol may loosen the cell membrane rigidity, which may result in the induction of trehalose biosynthesis for stress protection. Increased production of trehalose may increase galactose uptake by consuming glucose-1-phosphate, which is a feed-forward inhibitor of Fgm2 (17). However, in the present study, only a negligible effect of mutation in the ergosterol pathway on galactose metabolism was detected. This result means that the ERG5Pro370 (EBU) mutation has no direct effect on improving galactose utilization, and this may be the reason why EBU only showed a very small improvement in galactose utilization (Fig. 1). It is, however, interesting that the unique changes in the ergosterol pathway observed in the evolved mutant 62B may be derived from not only the ERG5Pro370 (EBU) mutation but also the RAS2Tyr112 (RBU) mutation.

Combination of PGM2 overexpression and mutations in RAS2 and ERG5 recovers adaptive phenotypes in galactose utilization. The combination of ERG5Pro370 mutation with PGM2 overexpression (EBP strain) showed a pattern similar to those of the other combined strains, which not only indicate a role for ERG5Pro370 in ergosterol metabolism but also suggest that it has a positive interaction with PGM2 overexpression for improving galactose utilization. PGM2 overexpression by constitutive promoter in a high-copy-number plasmid (PGM2 strain) mainly increased fermentation, as seen in the higher specific ethanol production rate and upregulation of organelle related genes (Fig. 1 and 3) (8, 19). When the three point mutations were combined with PGM2 overexpression, the metabolism changed to have increased respiration, resulting in a higher maximum specific growth rate and thereby also a higher biomass yield on galactose...
with downregulation of stress related signaling ERK/MAPK targets, which are related to stress response of osmolarity and starvation. PGM2 overexpression in RAU and RBU strains, which already showed upregulation of this gene, may somehow result in different Pgm2p functions that could not only be dedicated to galactose metabolism but also to the cellular state. The main function of PGM2 (phosphoglucomutase) is the conversion of glucose-1-phosphate to glucose-6-phosphate, but other functions such as involvement in the synthesis of cell wall and cellular calcium homeostasis have been reported (6, 12). Moreover, conditional posttranscriptional modification of PGM2 has been reported (9, 11). This modification is controlled by culture conditions such as heat shock and carbon sources.

In conclusion, we found that only a few mutations identified in adaptively evolved yeast strains are necessary to confer the same gross phenotype. Furthermore, these mutations may be additive in the sense that the overexpression of a single gene may result in a large genome-wide transcriptional response, but when this overexpression is combined with point mutations, many of these transcriptional changes disappear. This is most likely due to an effect of regulation of cellular stress response in the mutations of the Ras/PKA signaling pathway. Thus, it is clear that the use of adaptive evolution with the identification of beneficial changes is a powerful strategy in metabolic engineering since it allows for the identification of strategies that involves modulation of the cellular regulatory system.

ACKNOWLEDGMENTS

We thank the CJ CheilJedang Doctoral Fellowship for financial support (to K.-K.H.). We acknowledge financial contributions from the Chalmers Foundation, The Knut and Alice Wallenberg Foundation, the European Union-funded project UNICELLSYS (contract 201142), the European Research Council (grant 247013), and the Novo Nordisk Foundation.

REFERENCES